Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.01 SGD | 0.00% | 0.00% | -37.50% |
Valuation
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Capitalization 1 | 81.71 | 80.18 | 90.02 | 65.42 | 23.49 | 9.905 |
Enterprise Value (EV) 1 | 76.63 | 93.1 | 96.04 | 63.09 | 24.4 | 12.41 |
P/E ratio | -4.41 x | -6.85 x | 147 x | -3.27 x | -2.11 x | -0.31 x |
Yield | - | - | - | - | - | - |
Capitalization / Revenue | 13.3 x | 3.72 x | 2.48 x | 1.92 x | 1.43 x | 0.86 x |
EV / Revenue | 12.5 x | 4.32 x | 2.65 x | 1.85 x | 1.49 x | 1.08 x |
EV / EBITDA | -9.47 x | -20.1 x | 46.7 x | -30 x | 121 x | -2.79 x |
EV / FCF | -9.36 x | -15.3 x | -654 x | -17.9 x | 4.47 x | -6.87 x |
FCF Yield | -10.7% | -6.53% | -0.15% | -5.59% | 22.4% | -14.6% |
Price to Book | 1.71 x | 1.59 x | 1.49 x | 1.25 x | 0.57 x | 0.97 x |
Nbr of stocks (in thousands) | 489,311 | 580,984 | 612,405 | 617,215 | 618,210 | 619,052 |
Reference price 2 | 0.1670 | 0.1380 | 0.1470 | 0.1060 | 0.0380 | 0.0160 |
Announcement Date | 4/9/19 | 4/14/20 | 4/8/21 | 4/10/22 | 6/12/23 | 4/11/24 |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Net sales 1 | 6.135 | 21.53 | 36.26 | 34.12 | 16.41 | 11.49 |
EBITDA 1 | -8.092 | -4.624 | 2.056 | -2.101 | 0.201 | -4.442 |
EBIT 1 | -9.191 | -7.353 | -1.715 | -5.116 | -1.461 | -4.769 |
Operating Margin | -149.81% | -34.15% | -4.73% | -14.99% | -8.9% | -41.51% |
Earnings before Tax (EBT) 1 | -18.73 | -11.43 | 2.115 | -17.89 | -11.24 | -34.37 |
Net income 1 | -18.45 | -10.51 | 0.615 | -19.97 | -11.14 | -32.2 |
Net margin | -300.7% | -48.81% | 1.7% | -58.52% | -67.9% | -280.23% |
EPS 2 | -0.0379 | -0.0201 | 0.001000 | -0.0324 | -0.0180 | -0.0520 |
Free Cash Flow 1 | -8.188 | -6.084 | -0.1468 | -3.528 | 5.456 | -1.806 |
FCF margin | -133.46% | -28.25% | -0.4% | -10.34% | 33.24% | -15.72% |
FCF Conversion (EBITDA) | - | - | - | - | 2,714.24% | - |
FCF Conversion (Net income) | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - |
Announcement Date | 4/9/19 | 4/14/20 | 4/8/21 | 4/10/22 | 6/12/23 | 4/11/24 |
Balance Sheet Analysis
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Net Debt 1 | - | 12.9 | 6.02 | - | 0.91 | 2.5 |
Net Cash position 1 | 5.08 | - | - | 2.34 | - | - |
Leverage (Debt/EBITDA) | - | -2.796 x | 2.929 x | - | 4.542 x | -0.5633 x |
Free Cash Flow 1 | -8.19 | -6.08 | -0.15 | -3.53 | 5.46 | -1.81 |
ROE (net income / shareholders' equity) | -35.2% | -23.8% | 3.79% | -31% | -22.2% | -110% |
ROA (Net income/ Total Assets) | -8.73% | -5.76% | -1.1% | -3.56% | -1.3% | -7.26% |
Assets 1 | 211.2 | 182.6 | -55.77 | 561.2 | 859.8 | 443.4 |
Book Value Per Share 2 | 0.1000 | 0.0900 | 0.1000 | 0.0800 | 0.0700 | 0.0200 |
Cash Flow per Share 2 | 0.0100 | 0.0100 | 0.0200 | 0.0200 | 0.0100 | 0.0100 |
Capex 1 | 1.68 | 1.71 | 1.08 | 0.75 | 0.68 | 0.42 |
Capex / Sales | 27.32% | 7.94% | 2.98% | 2.19% | 4.14% | 3.62% |
Announcement Date | 4/9/19 | 4/14/20 | 4/8/21 | 4/10/22 | 6/12/23 | 4/11/24 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
1st Jan change | Capi. | |
---|---|---|
-37.50% | 4.55M | |
-14.92% | 84.68B | |
+13.30% | 81.12B | |
+11.62% | 29.4B | |
-12.71% | 16.73B | |
-3.06% | 16.36B | |
-2.63% | 14.92B | |
-31.75% | 11.77B | |
-1.42% | 11.72B | |
+27.44% | 11.71B |
- Stock Market
- Equities
- 1H3 Stock
- Financials Clearbridge Health Limited